Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Decitabine/Tetrahydrouridine in Advanced Pancreatic Cancer
NCT02847000Phase 1Completed
- Start
- Dec 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of decitabine in pancreatic adenocarcinoma (PDAC). Primary endpoint: DNMT1 protein level decreases up to 12 months. Started Dec 2016; status: completed.
02
Drugs
decitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02847000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02847000.